The Democratic Republic of the Congo has confirmed Bundibugyo Ebola in three provinces: Ituri, North Kivu and South Kivu. The CDC's July 9 situation record reports 1,759 confirmed cases and 600 deaths as of July 7. [1] The larger toll is grave, but the map tells responders where the outbreak is established.
It does not establish the disease everywhere a possible case has appeared. AP reports suspected cases in Tshopo and Haut-Uele, including a case in Kisangani with no apparent geographic link to the known outbreaks. [2] Suspected is an evidence stage, not a synonym for confirmed. The Kisangani investigation matters precisely because its connection remains unresolved.
The paper reported Wednesday that the treatment trial and testing throughput measured the response better than the death milestone. That position survives the higher count. AP reported the trial's first enrollment on July 2; it evaluates the monoclonal antibody MBP134, the antiviral remdesivir, both together, and standard care alone. The report supplies no trial result. [3]
The trial and the map answer different questions. The province record asks where disease has been confirmed. The treatment study asks whether either candidate therapy, alone or in combination, changes patient outcomes. Starting that machinery is evidence of a response, not evidence that a treatment works. AP reports that survival will be tracked for 28 days and that results could take months; it supplies no interim safety or survival result. [3]
These distinctions create three different maps. The first contains provinces with confirmed disease. The second contains provinces where suspected cases require investigation. The third is the response map: laboratories, treatment sites, trial enrollment and deployed staff. Collapsing the three produces a dramatic shape and a useless one.
The CDC says about 400 staff are involved in the response and more than 120 are deployed. [1] Those numbers describe machinery, not success. They do not prove that a suspected case belongs to a known chain, that either treatment improves survival, or that the outbreak is contained. They show that investigators and clinicians are present to answer those questions.
The rise from Wednesday's reported 506 deaths to the current 600 also cannot answer the geographic question by itself. A toll aggregates human loss across the outbreak. It does not reveal whether Tshopo or Haut-Uele has crossed from suspected to confirmed status, or whether the Kisangani investigation has found a connection. Those changes require case and tracing evidence, not arithmetic.
Kisangani is the sharpest test. If the case is confirmed and investigators cannot connect it to a known transmission chain, the operational problem changes. If testing rules it out or tracing finds a link, the map changes differently. Until that work is complete, writing Tshopo as a confirmed province would replace surveillance with speculation.
The same restraint applies to Haut-Uele. Its appearance in a suspected-case report is a reason to watch the investigation, not permission to color the province as confirmed. Maps look authoritative even when their categories are sloppy. Here the categories carry the most important fact in the story: what responders know, and what they are still testing.
Mainstream coverage has an obvious headline in the 600-death threshold. A social-media panic frame would make each new province proof of uncontrolled continental spread or an imported threat to distant crowds, but no verified X post supports that account. The paper cannot use an imagined panic as evidence.
The useful account is quieter and more exact. Three provinces are confirmed. Two others have suspected cases. One apparently unlinked case is under investigation. Two treatments are being studied, with no result yet reported. A death total records the cost already paid; the confirmed-versus-suspected map and the trial machinery record what the response still has to learn.
-- KENJI NAKAMURA, Tokyo